



# Pharmaceutical Biotechnology for Beginners

An Overview and Insight in pharmaceutical  
Biotechnology

2-3 May 2012, Vienna, Austria

## SPEAKERS:

**Dr Falk Klar**  
*IDT, Germany*

**Dr Markus Fido**  
*Vela Laboratories, Austria*

**Arjan Langen**  
*MSD, The Netherlands*

## LEARNING GOALS:

- Introduction into Biotechnology
- GMP Guidelines in Biotechnology
- Master and Working Cell Banks
- GMP Requirements on Rooms and Personnel
- Biotechnical Manufacturing of API - Focus on E.coli
- Biotechnical Manufacturing of API - Cell Cultures
- Virus Reduction
- Fill and Finish
- Clinical Studies and Authorisation



EUROPEAN COMPLIANCE  
ACADEMY





+ 49 6221 84 44 34

Reservation Form (Please complete in full)

**Pharmaceutical Biotechnology for Beginners**

2-3 May 2012, Vienna, Austria

Mr.  Ms

Title, first name, surname

Company

Department

**Important: Please indicate your company's VAT ID Number**

**P.O. Number, if applicable**

Street/P.O. Box

City

Zip Code

Country

Phone/Fax

E-Mail (please fill in)

If the bill-to-address deviates from the specifications on the right, please fill out here:

---

---

---

---

---

---

---

---

CONCEPT HEIDELBERG  
 P.O. Box 101764  
 Fax +49 (0) 62 21/84 44 34  
  
 D-69007 Heidelberg  
 GERMANY

**General terms and conditions**

- If you cannot attend the conference you have two options:  
 1. We are happy to welcome a substitute colleague at any time.  
 2. If you have to cancel entirely we must charge the following processing fees: Cancellation
- until 2 weeks prior to the conference 10 %
  - until 1 weeks prior to the conference 50 %
  - within 1 week prior to the conference 100 %.

CONCEPT HEIDELBERG reserves the right to change the materials, instructors, or speakers without notice or to cancel an event. If the event must be cancelled, registrants will be notified as soon as possible and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be responsible for discount airfare penalties or other costs incurred due to a cancellation.  
**Terms of payment:** Payable without deductions within 10 days after receipt of invoice.  
**Important:** This is a binding registration and above fees are due in case of cancellation or non-appearance. If you cannot take part, you have to inform us in writing. The cancellation

fee will then be calculated according to the point of time at which we receive your message. In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receipt of payment will not be confirmed).

**Date**

Wednesday, 2 May 2012, 09.30 h – 18.00 h  
 (Registration and coffee 09.30 -10.00 h )  
 Thursday, 3 May 2012, 08.30 h – 17.00 h

**Venue**

RENAISSANCE WIEN HOTEL  
 Linke Wienzeile – Ullmannstrasse 71  
 A-1150 Vienna, Austria  
 Phone +43 1 89102  
 Fax +43 1 89102 – 300

**Fees**

ECA Members € 1.490,- per delegate plus VAT  
 APIC Members € 1,590- per delegate plus VAT (does not include ECA Membership)  
 Non-ECA Members € 1.690,- per delegate plus VAT  
 EU GMP Inspectorates € 845,- per delegate plus VAT  
 The conference fee is payable in advance after receipt of invoice and includes conference documentation, dinner on the first day, lunch on both days and all refreshments. VAT is reclaimable.

**Accommodation**

CONCEPT HEIDELBERG has reserved a limited number of rooms in the conference hotel. You will receive a room reservation form when you have registered for the event. Please use this form for your room reservation or be sure to mention "ECA7276" to receive the specially negotiated rate (single room € 129,- per night incl. breakfast) for the duration of your stay. Reservation should be made directly with the hotel not later than 20 March 2012. Early reservation is recommended.

**Registration**

Via the attached reservation form, by e-mail or by fax message. Or you register online at [www.gmp-compliance.org](http://www.gmp-compliance.org).

**Conference language**

The official conference language will be English.

**Organisation and Contact**

CONCEPT HEIDELBERG  
 P.O. Box 10 17 64  
 D-69007 Heidelberg, Germany  
 Phone +49 (0) 62 21/84 44-0  
 Fax +49 (0) 62 21/84 44 34  
 E-mail: info@concept-heidelberg.de  
[www.concept-heidelberg.de](http://www.concept-heidelberg.de)

**For questions regarding content:**  
 Axel H. Schroeder (Operations Director) at +49-62 21/84 44 10 or per e-mail at [schroeder@concept-heidelberg.de](mailto:schroeder@concept-heidelberg.de).  
**For questions regarding reservation, hotel, organisation etc.:**  
 Ronny Strohwalde (Organisation Manager) at +49-62 21/84 44 51 or per e-mail at [strohwalde@concept-heidelberg.de](mailto:strohwalde@concept-heidelberg.de).

# Pharmaceutical Biotechnology for Beginners

2 -3 May 2012, Vienna, Austria

## Objectives

---

This course will provide non-Biotechnologists with an overview and insight in pharmaceutical biotechnology. It will also present the opportunities of biotechnology in GMP manufacturing.

Common aspects of production analytics will be discussed just as well as regulatory aspects of Biopharmaceuticals (bacteria and cell culture) and specific requirements on clinical studies and marketing authorisation. It will furthermore concentrate on topics like virus reduction, cell banking, media fills and dedicated rooms and personnel. The course will be completed by a presentation of the current comprehensive bodies of legislation.

## Background

---

From a historical view, Biopharmaceuticals are no new business. Antibiotics and vaccines have been well known for more than 60 years. But with the marketing authorisation of the first pharmaceutical product, produced by gene technology in the 80s, a new era of biopharmaceutical and biotechnological development and manufacturing started.

In 2007, 20% of all new released pharmaceuticals were Biopharmaceuticals. Future pharmaceutical products based on Biotechnology and the Biosimilars (Bio-generics) will become more and more important and present a higher share of pharmaceutical products

## Target Audience

---

This Course is addressed to those interested in pharmaceutical biotechnology related to GMP manufacturing and marketing authorisation.

## Moderator

---

Axel H. Schroeder, Concept Heidelberg

## Programme

---

### What is Biotechnology/Introducing in Biotechnology

- Definition of Biotechnology/Biopharmaceuticals
- Small Chemical Entities versus Biopharmaceuticals
- History of production and analytics
- View into different areas of the business
- Market and future investigations

Markus Fido

### GMP Guidelines in Biotechnology

- European Guidelines
- FDA Guidelines
- ICH
- ISPE
- PIC/S
- PDA
- WHO
- APIC
- ISO

Falk Klar

### Manufacturing of biotechnological API – Focus on E. coli

- Suitability of raw material
- TSE safety of raw materials
- Water as raw material
- Fermentation
- Cell harvesting
- Purification
- Filling of bulk API
- From drug substance to drug product

Falk Klar

### Manufacturing of Biotechnological API – Focus on Cell Culture

- Different cell lines as production platforms
- The manufacturing process (up/downstream)
- Contamination risks during cell culture and production
- Analytical methods for product characterisation
- Quality & Regulatory aspects

Markus Fido

### Clinical Studies/ Authorisation

- Clinical studies and drug regulatory affairs for biotechnological products
- From preclinical to clinical studies
- Bioanalytics during clinical trials
- Centralised procedure is favourite
- Changes and variations of biotechnological products

Markus Fido

## GMP Requirements for Rooms and Personnel

- Regulatory requirements
- Balancing GMP and laws of gene technology
- Zone concept
- Flow of material and personnel
- Clean rooms
- Cleaning and hygiene procedures
- Monitoring and validation

Falk Klar

## GMP Requirements for Master- and Working Cell Banks

- From initial cell to product
- Manufacturing
- Storage
- Quality Control
- Release Documentation

Falk Klar

## Virus Reduction

- Regulatory background
- Relevant and model viruses
- Common and new methods of virus reduction
- TSE Safety

Arjan Langen

## Fill and Finishing

- Aseptic processing and media fill
- Liquid formulation or lyophilisation?
- Stability tests of Biopharmaceuticals

Arjan Langen

## Social Event

---

On 2 May 2012, you are cordially invited to a social event. This is an excellent opportunity to share your experiences with colleagues from other companies in a relaxed atmosphere.



## Speakers

---

### Dr Falk Klar

*IDT GmbH, Germany*

After completing his studies in physics and obtaining the PhD, Falk Klar started his industrial career in a medical device company. Between 1995 and 1999 he was responsible for organisation, conducting and data evaluation of preclinical and clinical studies. During that time he attended a qualification programme to become a Quality Manager. In 1999 he joined an international Contract Research Organisation as Project Manager responsible for conducting clinical trials in phases I to IV. Between 2002 and 2009 Dr Klar was employed as Head of Quality Assurance of Biomeva GmbH, a biotech Contract Manufacturing Organisation producing APIs. He gained comprehensive experience in the wide spectra of GMP quality management including validation of manufacturing processes and computerised systems. In 2010 Dr Klar joined IDT Biologika GmbH, a global supplier to the pharmaceutical and biotechnology industry. In his recent position of Chief Compliance Officer he is responsible for all quality assurance and compliance aspects in the branches human vaccines, contract manufacturing of biopharmaceuticals and animal health.

### Dr Markus Fido

*Vela, Austria*

Markus Fido is CEO and Founder of Vela Laboratories, where he is responsible for Finance & Controlling Regulatory Affairs & Quality Operations. Before that he was Head Quality Control at Igeneon / Apton Biopharma AG where he was in charge for all QC aspects of pre-clinical and clinical projects such as stability studies, specifications, method validation, and product release. Prior he was working as a Group Leader of Immunology and Product Development at Biomin GmbH, Head Biochemical Control at Baxter AG and Head Quality Operations at Octapharma GmbH. His focus is GMP/GCP concerns during the development of Biopharmaceuticals, Biosimilars and Biologics. He holds a Ph.D. in biochemistry and molecular microbiology from the Technical University in Graz (Austria).

### Arjan Langen

*MSD, The Netherlands*

Arjan Langen was manager of Microbiological Quality Control and Quality Assurance officer at Intervet International in The Netherlands before he joined Nobilon International. At Nobilon he was appointed Quality Assurance Manager, responsible for the cGMP-approval of the new multi-purpose vaccine production facility in Boxmeer, The Netherlands. 2008 Arjan takes over the position of Director Compliance at DSM. In 2009 he founded his own company for training and consulting. He is a member of the PDA and a member of the Dutch Society of Pharmaceutical Microbiology.